Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update
ACXPSTATEN ISLAND, N.Y., Aug. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and...
Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds
ACXPSTATEN ISLAND, N.Y., June 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (Acurx or the Company), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a...
Acurx Pharma Says Lead Antibiotic Candidate, Ibezapolstat, Is Ready To Advance To International Pivotal Phase 3 Clinical Trials For Treatment Of Patients With C. Difficile Infection
ACXPHC Wainwright & Co. Assumes Acurx Pharmaceuticals at Buy, Announces Price Target of $8
ACXPAcurx Pharmaceuticals Q1 EPS $(0.11) Beats $(0.15) Estimate
ACXPA Look Ahead: Acurx Pharmaceuticals's Earnings Forecast
ACXPThe Indian Patent Office Granted A New Patent To Acurx Pharmaceuticals In March 2025. This Patent Relates To DNA Polymerase IIIC Inhibitors, Including Compositions-Of-Matter
ACXPHC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $12 Price Target
ACXPAcurx Pharmaceuticals FY 2024 GAAP EPS $(0.87) Beats $(1.52) Estimate
ACXPDow Dips Over 250 Points; Genesco Shares Plunge After Q4 Results
ACXPWhy Acurx Pharmaceuticals (ACXP) Shares Are Down 30%
ACXPAcurx Pharmaceuticals shares are trading lower by 30% during Friday's session. The company announced a $1.1 million registered direct offering.
Acurx Pharmaceuticals Announced $1.1M Registered Direct Offering Of 2.745M Shares Of Its Common Stock At A Purchase Price Of $0.40 Per Share
ACXPAcurx Announces Publication Of Nonclinical In Vivo Data In The Journal Of Antimicrobial Agents And Chemotherapeutics Entitled: Microbiome Impact Of Ibezapolstat And Other Clostridioides Difficile Infection-relevant Antibiotics Using Humanized Mice Differe
ACXPAcurx Pharmaceuticals Granted Japan Patent For DNA Polymerase IIIC Inhibitors
ACXPHC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $12 Price Target
ACXPHC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $12 Price Target
ACXPAcurx Pharmaceuticals Announced Today That The Company's Board Of Directors Approved The Purchase Of Up To $1 Million In Bitcoin To Hold As A Treasury Reserve Asset
ACXPHC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $12 Price Target
ACXP12 Health Care Stocks Moving In Tuesday's After-Market Session
ACXPHC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $12 Price Target
ACXP